ReviewFrontiers in oncology2026
Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is one of the most common malignant tumors in women, and its incidence is rising continuously worldwide. According to recent global cancer statistics, there were about 417,000 new cases and 97,000 deaths from EC in 2020(1). The standard treatment for EC is hysterectomy, which undoubtedly deprives some young patients of their fertility. Fertility-sparing treatment (FST) for endometrial cancer allows these women to preserve fertility before undergoing standard treatment. Traditional fertility-sparing regimens are mainly based on progestin. However, in recent years, with the application of molecular classification, some studies have found that among patients undergoing FST, women with POLE mutations (POLE-mut) often have a higher complete remission (CR) rate, while those with P53 abnormal (P53abn) or mismatch repair deficiency (dMMR) have poor prognosis. Among them, patients with dMMR endometrial cancer seem to have a higher recurrence rate after achieving complete remission through progestin treatment. Currently, fertility-sparing treatment regimens for dMMR patients are being gradually studied, and immune checkpoint inhibitors (ICIs) may play a key role in the treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.